Related Experiment Video
Updated: Feb 22, 2026

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
Published on: November 7, 2017
The problem of cardio-renal diseases in patients with gout
1a Division of Internal Medicine and Nephrology, School of Internal Medicine , University of L'Aquila, San Salvatore Hospital Coppito , L'Aquila , Italy.
Insights
High uric acid levels (hyperuricemia) may play a role in heart and kidney disease. Further research is needed to confirm if lowering uric acid benefits cardiovascular and renal health.
Area of Science:
- Cardiology
- Nephrology
- Metabolic Disorders
Background:
- Mounting evidence suggests a role for hyperuricemia in cardio-renal disease.
- Uncertainty persists regarding hyperuricemia as a major causal cardiovascular risk factor.
- Treatment may benefit patients with hyperuricemia accompanying specific conditions like gout, CKD, or cardiovascular risk factors.
Purpose of the Study:
- To evaluate the evidence for hyperuricemia's role in cardio-renal disease.
- To determine if lowering uric acid levels is clinically beneficial for cardiovascular and renal health.
- To explore the potential benefits of reducing serum uric acid in the general population.
Main Methods:
- Literature analysis to assess existing evidence on hyperuricemia and cardio-renal outcomes.
- Identification of conditions where hyperuricemia treatment might be beneficial.
- Review of data supporting clinical trials for uric acid-lowering therapies.
Main Results:
- Sufficient evidence exists to warrant clinical trials on lowering uric acid levels.
- Potential benefits of treatment are suggested even without overt gout.
- Hyperuricemia's association with urate deposition, CKD, and cardiovascular risk factors is noted.
Conclusions:
- Clinical trials are recommended to ascertain the benefits of reducing uric acid in cardiovascular and renal disease prevention and treatment.
- Investigating the reduction of serum uric acid levels below 5.0 mg/dL in the general population is practically important.
Backgrounds:
Although evidence is mounting on the role of hyperuricemia in cardio-renal disease, continuing doubt remains as to whether hyperuricemia can be considered a major causal cardiovascular risk factor. In addition, available data suggest that treatment may be beneficial, even in the absence of overt gout, when hyperuricemia accompanies other clinical conditions, such as urate deposition, advanced chronic kidney disease, or cardiovascular risk factors.
Methods And Results:
Analysis of the literature suggests there would be sufficient evidence warranting clinical trials to determine whether lowering uric acid levels would be clinically beneficial in the prevention or treatment of cardiovascular and renal diseases.
Conclusion:
Under a practical profile, it becomes progressively more important to investigate the possibility of reducing serum uric acid levels in the general population below the level of 5.0 mg/dL.
Related Concept Videos
Heart Failure Drugs: Diuretics
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management

